This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Sangamo Therapeutics (SGMO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
by Zacks Equity Research
Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.
Gilead's (GILD) Harvoni and Descovy Get Approval in China
by Zacks Equity Research
Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.
Gilead (GILD) Announces Data on CAR T Therapy Candidate
by Zacks Equity Research
Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Gilead's Vemlidy Gets Approval in China for HBV Infection
by Zacks Equity Research
Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.
Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
by Zacks Equity Research
Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 0.00% and -41.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.
Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View
by Zacks Equity Research
Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
by Zacks Equity Research
To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.
Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Gilead's Rheumatoid Arthritis Drug Successful in Phase III
by Zacks Equity Research
Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.
Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint
by Zacks Equity Research
Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Gilead's CAR-T Therapy Yescarta Gets Approval in Europe
by Zacks Equity Research
Gilead's (GILD) CAR-T therapy, Yescarta gets approval in Europe for adult patients suffering from relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy.
Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -13.33% and -31.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: Illumina (ILMN)
by Madeleine Johnson
Invest in the medical space with this DNA sequencing-focused company.
Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit
by Zacks Equity Research
Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.
Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock
by Zacks Equity Research
Sangamo Therapeutics (SGMO) needs investors to pay close attention to the stock based on moves in the options market lately.